Clinical Trial

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

Study acronym: COSMO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included. The local ablative therapy (LAT) may consist of stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, surgery or radiofrequency ablation (RFA).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-03-21; most recent amendment 2025-02-03.
Status change: Active, Not Recruiting → Recruiting 2023-04-25
Status change: Not Yet Recruiting → Active, Not Recruiting 2022-10-11
Trial Details
NCT Number NCT05301881
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Maarten van de Weijden Foundation
Conditions Breast Cancer Invasive, Metastatic Cancer, Oligoprogressive
Enrollment 118 participants
Start Date 2023-04-17
Primary Completion 2035-04-01 (estimated)
Study Completion 2040-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-05